ArQule

About

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs

Woburn,Massachusetts,United States
11 - 50

Highlights

Details

Last Funding Type: Post-IPO Equity
Industries: Biotechnology,Pharmaceutical,Therapeutics
Founded date: Jan 1, 1993
Number Of Employee: 11 - 50
Operating Status: Active
Stock Symbol: nasdaq:ARQL
Legal Name: ArQule, Inc.

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$9.50M

ArQule has raised a total of $9.50M in funding over 2 rounds. Their latest funding was raised on Nov 8, 2017 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Nov 8, 2017	Post-IPO Equity	$9.50M	1	—	—	Detail
Jan 19, 2011	Post-IPO Equity	—	—	—	—	Detail
Oct 25, 1996	IPO	—	—	—	—	Detail
Jan 1, 1994	Seed	—	1	—	—	Detail